No! The rumored partnership—the one reported in the Times of London a month ago—is a U.S. partnership for Pharming’s lead drug, Rhucin, an rhC1 inhibitor for the treatment of hereditary angiodema.
Although today’s Pharming news is a welcome development, it does not have anywhere near the importance of a U.S. partnership announcement for Rhucin.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”